Paroxysmal iatrogenic acne and the epidermal growth factor receptor inhibitors (EGFR);Acné iatrogène paroxystique et les inhibiteurs du récepteur du facteur de croissance épidermique (EGFR)

Revue Medicale de Liege

Volumn 62, Issue 1, 2007, Pages 11-14

  Pierard Franchimont C ^b   Blaise, G ^b   Paquet, P ^c   Quatresooz, P ^c   Rorive, A ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Dermatologie   (Belgium)

^c NONE

Author keywords

Acne; Cancer; Cytostatic; Epidermal growth factor

Indexed keywords

ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ISOTRETINOIN; TETRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST;

ACNE; CANCER CHEMOTHERAPY; COMEDO; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; IATROGENIC DISEASE; INFLAMMATION; PARONYCHIA; SHORT SURVEY; SKIN INFLAMMATION; XEROSIS; ACNE VULGARIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; NEOPLASM; REVIEW; TREATMENT OUTCOME;

ACNE VULGARIS; ANTINEOPLASTIC AGENTS; HISTAMINE H1 ANTAGONISTS; HUMANS; IATROGENIC DISEASE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 34247190154     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (50)

1. Flagothier C, Piérard-Franchimont C, Piérard GE. - Acnés paroxystiques. Rev Med Liège, 2004, 59, 177-179.
2. Busam KJ, Capodieci P, Motzer R, et al. - Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol, 2001, 144, 1169-1176.
3. Kimyai-Asodi A, Jih MH. - Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol, 2002, 138, 129-130.
4. Walon L, Gilbeau C, Lachapelle JM. - Eruptions acnéiformes induites par le cétuximab. Ann Dermatol Venereal, 2003, 13, 443-446.
5. Fernandez-Galar M, Espana A, Lopez-Picazo JM. - Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol, 2004, 29, 138-140.
6. Jacot W, Bessis D, Jorda E, et al. - Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol, 2004, 151, 238-241.
7. Lee MW, Seo CW, Kim SW, et al. - Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol, 2004, 84, 23-26.
8. Segaert S, Van Cutsem E. - Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 2005, 16, 1425-1433.
9. Kerre S. - Eruptions acnéiformes et périonyxis induits par le cetuximab, un facteur de croissance anti-épidermique dans le traitement des tumeurs solides métastasées. Dermatol Actual, 2006, 95, 24-25.
10. Wyatt JA, Leonard GD, Sachs DL. - Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol, 2006, 7, 45-63.
11. Albanell J, Codony-Servat J, Rojo F, et al. - Activated extracellular signal-regulated kinases : association with epidermal growth factor receptor-transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res, 2001, 61, 6500-6510.
12. Baselga J. - The EGFR as a target for anticancer therapy, focus on cetuximab. Eur J Cancer, 2001, 37, S16-S22.
13. Pederson MW, Meltorn M, Damstrup L. - The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol, 2001, 12, 745-760.
14. Robert F, Ezekiel MP, Spencer SA, et al. - Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head an neck cancer. J Clin Oncol, 2001, 19, 3234-3243.
15. Bunn JPA, Franklin W. - Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol, 2002, 29, 38-44.
16. Herbst RS, Langer CJ. - Epidermal growth factor receptors as a target for cancer treatment : the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol, 2002, 29, 27-36.
17. Vogel CL, Cobleigh MA, Tripathy D, et al. - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002, 20, 719-726.
18. Castillo L, Etienne-Grimaldi MC, Fischel JL, et al. - Pharmacological background of EGFR targeting. Ann Oncol, 2004, 15, 1007-1012.
19. Roskoski JR. - The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun, 2004, 319, 1-11.
20. Vanhoefer U, Twes M, Rojo F, et al. - Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 2004, 22, 175-184.
21. Nanney LB, Magid M, Stoscheck CM, King Le Jr. - Comparison of epidermal growth factor binding and receptor distribution in ormal human epidermis and epidermal appendages. J Invest Dermatol, 1984, 83, 385-393.
22. Piérard-Franchimont C, Colige A, Arrese-Estrade J, et al. - Immunohistochemical expression of epidermal growth factor receptors in nuclei of a subpopulation of keratinocytes and sweat gland cells. Dermatologica, 1991, 183, 7-9.
23. Piérard GE, Paquet P, Avila-Camacho M, et al. - Cytokine profile in acne. Giorn Int Dermatol Pediatr, 1997, 9, 113-116.
24. Lotem M, Hubert A, Lyass O, et al. - Skin toxic effects of polyethelyne glycol-coated liposomal doxorubicin. Arch Dermatol, 2000, 136, 1475-1480.
25. Epstein JEH, Lutzner MA. - Folliculitis induced by actinomycin D. N Engl J Med, 1969, 281, 1094-1096.
26. Kris MG, Natale RB, Herbst RS, et al. - Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : a randomized trial. JAMA, 2003, 290, 2149-2158.
27. Perez-Soler R. - Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome ? Oncology, 2003, 11, 23-28.
28. Saltz L, Kies M, Abbruzzese JL, et al. - The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol, 2003, 22, 204.
29. Mohamed MK, Ramalingam S, Lin Y, et al. - Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small-cell lung cancer. Ann Oncol, 2005, 16, 780-785.
30. Susman E. - Rash correlates with tumour response after cetuximab. Lancet Oncol, 2004, 5, 647.
31. Boucher KW, Davidson K, Mirkhur B, et al. - Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol, 2002, 45, 632-633.
32. Dainichi T, Tanaka M, Tsuruta N, et al. - Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 2003, 207, 324-325.
33. Nakano J, Nakamura M. - Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol, 2003, 42, 34-346.
34. Chang GC, Ynag T-Y, Chen K-C, et al. - Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 2004, 22, 4446-4448.
35. Dueland S, Sauer T, Lund-Johansen F, et al. - Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol, 2003, 42, 345-346.
36. Pascual JC, Banuls J, Belinchon I, et al. - Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol, 2004, 151, 1111-1112.
37. Santoro F, Cozzani E, Parodi A. - Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor. J Dermatol Treat, 2006, 17, 160-161.
38. Pérez-Soler R, Delord JP, Halpern A, et al. - HER1/EGFR inhibitor-associated rash : future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist, 2005, 10, 345-356.
39. Gutzmer R, Werfel T, Mao R. - Successful treatment with oral isotretinion of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol, 2005, 153, 849-850.
40. Rhee J, Oishi K, Garey J, et al. - Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin Colorect Cancer, 2005, 5, S101-S106.
41. Segaert S, Tabernero J, Chosidow O. - The management of skin reaction in cancer patients receiving epidermal growth factor targeted therapies. J German Soc Dermatol, 2005, 8, 599-605.
42. Xhauflaire-Uhoda E, Goffin V, Piérard-Franchimont C, et al. - Comment je traite ... l'acné de l'adolescent : un algorithme stratégique sans antibiotique. Rev Med Liège, 61, 10, 667-670.
43. Thirion L., Piérard-Franchimont C, Piérard G.E. - Atténuer l'acné qui couve par un traitement cosmétique. Skin, 2006, 9, 37-38.
44. Piérard GE, Piérard-Franchimont C. - Skin immune downregulators : from bench to bedside. Curr Top Pharmacol, 2003, 7, 109-116.
45. Piérard-Franchimont C, Piérard G.E. - Beyond a glimpse at seasonal dry skin. A review. Exog Dermatol, 2002, 1, 3-6.
46. Xhauflaire-Uhoda E, Haubrechts C, Piérard-Franchimont C, et al. - Qualité de vie, emollients et agents hydratants. Rev Med Liège, 2006, 61, 233-236.
47. Paquet P, Piérard-Franchimont C, Henry F, et al. - Traitements par lasers et lumière pulsée. Rev Med Liège, 2005, 60, S118-S124.
48. Paquet P, Flagothier C, Piérard-Franchimont C, et al. - Les toxidermies paroxystiques graves. Rev Med Liège, 2004, 59, 286-292.
49. Paquet P, Piérard GE, Quatresooz P. - Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol, 2005, 136, 205-216.
50. Amador ML, Oppenheimer D, Perea S. - An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res, 2004, 64, 9139-9143.